Bortezomib treatment causes remission in a Ph+ ALL patient and reveals FoxO as a theranostic marker.

Posted by rob on March 5, 2011 under Uncategorized | Comments are off for this article

This study provides support that FoxO3 is a good biomarker for BCR-ABL-mediated leukemogenesis. Additionally, proteasomal inhibition by bortezomib may be a promising therapeutic option in Philadelphia-positive ALL, where FoxO3 is downregulated.
PMID: 21282974 [PubMed - as supplied by publisher] (Source: Cancer Biology and Therapy)
More